| Not Yet Recruiting | Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage Adult ALL, MPAL | N/A | 2026-06-30 |
| Not Yet Recruiting | BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | 2026-06-01 |
| Not Yet Recruiting | Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML AML | N/A | 2026-04-30 |
| Not Yet Recruiting | ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL Ph-Like, Acute Lymphoblastic Leukemia | N/A | 2026-04-30 |
| Not Yet Recruiting | VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML AML, Adult | Phase 3 | 2026-04-30 |
| Not Yet Recruiting | Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignanc Relapsed/Refractory B-Cell Malignancies | Phase 1 | 2026-04-15 |
| Not Yet Recruiting | The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantati HSCT, Hematologic Cancer | N/A | 2026-04-14 |
| Not Yet Recruiting | Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relaps Large B-Cell Lymphoma (LBCL) | Phase 1 / Phase 2 | 2026-04-05 |
| Not Yet Recruiting | Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL Ph+ ALL | N/A | 2026-04-01 |
| Not Yet Recruiting | A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patien Drug-Induced Liver Injury | — | 2026-03-31 |
| Not Yet Recruiting | Study on the Pharmacokinetic Characteristics of Liposomal Amphotericin B in Patients With Invasive Fungal Infe Invasive Fungal Infections | — | 2026-03-30 |
| Not Yet Recruiting | Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphom Indolent Lymphoma | Phase 1 / Phase 2 | 2026-03-20 |
| Not Yet Recruiting | Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD). cGVHD, HSCT | Phase 1 / Phase 2 | 2026-03-16 |
| Not Yet Recruiting | Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis Myelofibrosis (MF), HSCT | Phase 2 | 2026-03-16 |
| Not Yet Recruiting | Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia | EARLY_Phase 1 | 2026-03-15 |
| Not Yet Recruiting | Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed HSCT, Ph+ ALL | Phase 2 | 2026-03-14 |
| Not Yet Recruiting | Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Pro CMV Infection | — | 2026-03-14 |
| Not Yet Recruiting | The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT HSCT | Phase 2 | 2026-03-14 |
| Not Yet Recruiting | A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia Relapsed/Refractory Acute Myeloid Leukemia(AML) | Phase 1 | 2026-03-02 |
| Recruiting | Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (IT Immune Thrombocytopenia, Treatment | Phase 2 | 2026-03-01 |
| Recruiting | Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) Immune Thrombocytopenia, Treatment | Phase 2 | 2026-03-01 |
| Recruiting | PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） Hemophilia, Inhibitors | Phase 4 | 2026-03-01 |
| Not Yet Recruiting | Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblasti Acute Lymphoblastic Leukemia, Adult | N/A | 2026-03-01 |
| Not Yet Recruiting | MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myel Multiple Myeloma | Phase 2 | 2026-03-01 |
| Not Yet Recruiting | rhTPO Dose Escalation vs Eltrombopag Switch in ITP Primary Immune Thrombocytopenia (ITP) | N/A | 2026-03-01 |
| Not Yet Recruiting | Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease Sickle Cell Disease | N/A | 2026-03-01 |
| Not Yet Recruiting | Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refrac Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis, Refractory / Relapsing / Progressive Inflammatory Myopathy | Phase 1 | 2026-03-01 |
| Not Yet Recruiting | Early Clinical Study on the Use of Donor-derived EBV-specific T Cells for the Prevention of EBV Infection Afte Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation | EARLY_Phase 1 | 2026-02-28 |
| Recruiting | Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia Congenital Dyserythropoietic Anemia (CDA) | Phase 1 / Phase 2 | 2026-02-25 |
| Recruiting | Adverse Effects of ATG/ALG Therapy in Aplastic Anemia Aplastic Anaemia | — | 2026-02-23 |
| Not Yet Recruiting | The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytar Hematologic Malignancies | Phase 2 | 2026-02-20 |
| Not Yet Recruiting | IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Leukemia (PCL) | EARLY_Phase 1 | 2026-02-15 |
| Not Yet Recruiting | A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplanta aGVHD | Phase 1 / Phase 2 | 2026-02-14 |
| Not Yet Recruiting | SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma Relapsed and Refractory Multiple Myeloma (RRMM) | EARLY_Phase 1 | 2026-02-01 |
| Not Yet Recruiting | Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry Hemophilia | — | 2026-02-01 |
| Not Yet Recruiting | A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | N/A | 2026-01-30 |
| Recruiting | Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombo Immune Thrombocytopenia, Treatment | Phase 2 | 2026-01-28 |
| Not Yet Recruiting | JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL Relapsed/Refractory Pediatric B-ALL | EARLY_Phase 1 | 2026-01-20 |
| Recruiting | Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) Immune Thrombocytopenia, Treatment | Phase 2 | 2026-01-20 |
| Not Yet Recruiting | An Open-label Study of GC012F in Rheumatoid Arthritis. Rheumatoid Arthritis | EARLY_Phase 1 | 2026-01-15 |
| Not Yet Recruiting | IASO206 in Patients With Relapsed/Refractory Multiple Myeloma Relapsed/Refractory Multiple Myeloma (RRMM) | EARLY_Phase 1 | 2026-01-15 |
| Not Yet Recruiting | HID-HSCT Versus IST as First-line Treatment for SAA Aplastic Anaemia | N/A | 2026-01-14 |
| Not Yet Recruiting | Zuberitamab for EBV Infection Post-Allo-HSCT HSCT, EBV Infection | Phase 2 | 2026-01-14 |
| Not Yet Recruiting | A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0 Multiple Myeloma (MM) | EARLY_Phase 1 | 2026-01-10 |
| Recruiting | Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL Marginal Zone Lymphoma | Phase 2 | 2026-01-05 |
| Not Yet Recruiting | Perianal MBL-CRE Colonization and Infection in Allogeneic Hematopoietic Stem Cell Transplant Patients ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Carbapenem-resistant Enterobacterales | — | 2026-01-01 |
| Recruiting | CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies | Phase 1 | 2026-01-01 |
| Not Yet Recruiting | A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Do Waldenström Macroglobulinemia (WM) | Phase 2 | 2025-12-30 |
| Not Yet Recruiting | Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma Follicular Lymphoma | Phase 2 | 2025-12-25 |
| Not Yet Recruiting | Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma Mantle Cell Lymphoma | Phase 2 | 2025-12-20 |
| Recruiting | A Cohort Study on the Association Between the ANS Function and Acute GvHD Transplant-Related Disorder | — | 2025-12-18 |
| Not Yet Recruiting | Modified Conditioning Regimen for CML-BP CML,Blast Phase, HSCT | Phase 2 | 2025-12-15 |
| Not Yet Recruiting | Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Severe Aplastic Anemia, Refractory Aplastic Anemia, Newly Diagnosed Aplastic Anemia | Phase 1 / Phase 2 | 2025-12-15 |
| Not Yet Recruiting | The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia Aplastic Anemia, Refractory, Relapse | Phase 1 / Phase 2 | 2025-12-10 |
| Withdrawn | Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for In Leukemia, Myeloid, Acute | Phase 2 | 2025-12-10 |
| Not Yet Recruiting | Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia ITP - Immune Thrombocytopenia | Phase 2 / Phase 3 | 2025-12-01 |
| Not Yet Recruiting | Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy ALL, Adult | Phase 2 | 2025-12-01 |
| Recruiting | Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL Pediatric Acute Leukemia | N/A | 2025-12-01 |
| Not Yet Recruiting | A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Relapsed/Refractory B-cell ALL | Phase 1 | 2025-11-30 |
| Not Yet Recruiting | Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human DLBCL, CLL, FL | Phase 1 / Phase 2 | 2025-11-29 |
| Not Yet Recruiting | National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Immune Thrombocytopenia (ITP) | — | 2025-11-25 |
| Not Yet Recruiting | A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms Relapsed/Refractory B-Cell Neoplasms | Phase 1 | 2025-10-30 |
| Not Yet Recruiting | Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia DNMT3A Gene Mutation | Phase 1 | 2025-10-30 |
| Recruiting | Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantati ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia, MDS (Myelodysplastic Syndrome) | N/A | 2025-10-22 |
| Recruiting | Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML AML, IDH1 Mutation, Treatment | Phase 1 / Phase 2 | 2025-10-17 |
| Recruiting | Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytop Immune Effector Cell Associated Hematotoxicity | EARLY_Phase 1 | 2025-10-01 |
| Recruiting | A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for Fungal Disease | — | 2025-09-30 |
| Not Yet Recruiting | CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute M AML - Acute Myeloid Leukemia | EARLY_Phase 1 | 2025-09-30 |
| Not Yet Recruiting | A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Tr Infections, Cytomegalovirus | — | 2025-09-25 |
| Not Yet Recruiting | A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell The Relapsed/Refractory Multiple Myeloma (RRMM) | EARLY_Phase 1 | 2025-09-15 |
| Not Yet Recruiting | Clinical Observation on the Efficacy of Patient-Donor Derived Probiotics in Improving Intestinal Flora Disorde Acute Graft-Versus-Host Disease | N/A | 2025-09-15 |
| Recruiting | BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis Systemic Light Chain Amyloidosis | Phase 2 | 2025-09-04 |
| Recruiting | Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN | Phase 2 | 2025-09-04 |
| Recruiting | CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors Relapsed and Refractory CD5 Hematological Tumors | N/A | 2025-09-03 |
| Recruiting | Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia) | Phase 2 | 2025-09-01 |
| Not Yet Recruiting | Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobuline Waldenström Macroglobulinemia (WM) | Phase 1 | 2025-09-01 |
| Recruiting | The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients HIV Infected Individuals, HIV | Phase 1 | 2025-09-01 |
| Recruiting | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients AML, Adult | Phase 3 | 2025-08-31 |
| Recruiting | Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Mar Solitary Bone Plasmacytoma, Plasmacytoma of Bone, Plasma Cell Disorders | Phase 2 | 2025-08-25 |
| Recruiting | ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leu Multiple Myeloma, Plasma Cell Leukemia | Phase 2 | 2025-08-10 |
| Not Yet Recruiting | BCMA/CD3 BsAb Therapy for POEMS Syndrome POEMS Syndrome | Phase 2 | 2025-08-10 |
| Recruiting | MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma Multiple Myeloma, Newly Diagnosed | Phase 2 | 2025-08-10 |
| Recruiting | ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multipl Multiple Myeloma, Newly Diagnosed | Phase 2 | 2025-08-10 |
| Recruiting | A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma CRS - Cytokine Release Syndrome, Myeloma | Phase 2 | 2025-08-10 |
| Not Yet Recruiting | Effect of a Simplified Mindfulness Intervention on Health-related Quality of Life in Patients Undergoing Hemat Hematopoietic Stem Cell Transplantation | N/A | 2025-08-07 |
| Recruiting | Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP) Immune Thrombocytopenia, Treatment | Phase 2 | 2025-08-01 |
| Recruiting | Romiplostim N01 for Chemotherapy-induced Thrombocytopenia Chemotherapy-induced Thrombocytopenia, Romiplostim N01 | Phase 2 | 2025-08-01 |
| Recruiting | Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy Prolonged Cytopenia Following CAR-T Therapy | Phase 2 | 2025-08-01 |
| Recruiting | Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by T Myelodysplastic Syndromes | Phase 2 | 2025-07-24 |
| Recruiting | The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT AML (Acute Myelogenous Leukemia), AML | EARLY_Phase 1 | 2025-07-20 |
| Not Yet Recruiting | Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Aplastic Anemia Idiopathic | Phase 2 | 2025-07-20 |
| Not Yet Recruiting | A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma | Phase 1 | 2025-07-15 |
| Recruiting | Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study Cytokine Release Syndrome, ICANS | Phase 1 | 2025-06-28 |
| Recruiting | SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | 2025-06-28 |
| Recruiting | CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma | Phase 1 | 2025-06-28 |
| Recruiting | uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma | Phase 1 | 2025-06-28 |
| Recruiting | A Study of CT0596 in Plasma Cell Leukemia Plasma Cell Leukemia | EARLY_Phase 1 | 2025-06-25 |
| Not Yet Recruiting | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patien DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | 2025-06-20 |
| Recruiting | CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia Severe Aplastic Anemia, Relapse, Refractory | Phase 1 | 2025-06-19 |
| Not Yet Recruiting | Optimal Timing of Hepatitis B Vaccination After Transplants Transplant-Related Disorder, Hepatitis B Virus Infection, Vaccine Reaction | Phase 3 | 2025-06-01 |
| Recruiting | Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL CD7 Positive, T - Cell Lymphoma | Phase 2 | 2025-06-01 |
| Not Yet Recruiting | Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukem Hematopoietic Stem Cell Mobilization | N/A | 2025-05-30 |
| Recruiting | Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Im Primary Immune Thrombocytopenia (ITP) | Phase 2 | 2025-05-22 |
| Recruiting | A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Acute Myeloid Leukemia | Phase 1 | 2025-05-22 |
| Recruiting | Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Pa Invasive Fungal Disease | — | 2025-05-19 |
| Recruiting | Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma Relapsed or Refractory Aggressive B-cell Lymphoma | Phase 2 | 2025-05-09 |
| Not Yet Recruiting | Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | 2025-04-25 |
| Recruiting | Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Multiple Myeloma | N/A | 2025-04-09 |
| Recruiting | Newly-diagnosed Pediatric Ph-positive B-ALL Protocol Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic | Phase 3 | 2025-03-28 |
| Recruiting | CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma Multiple Myeloma | EARLY_Phase 1 | 2025-03-28 |
| Recruiting | Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficac Mucormycosis in Hematologic Malignancies | — | 2025-03-25 |
| Enrolling By Invitation | Cohort of Cord Blood Bank Health Status, Childhood Diseases | — | 2025-03-25 |
| Recruiting | BCMA CAR-T for Dynamic High-risk Multiple Myeloma Multiple Myeloma | Phase 2 | 2025-03-18 |
| Recruiting | Newly-diagnosed Pediatric T-cell ALL Protocol Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma | Phase 2 / Phase 3 | 2025-03-11 |
| Recruiting | Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk, Primary Refractory | Phase 1 / Phase 2 | 2025-03-03 |
| Recruiting | Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients Multiple Myeloma | Phase 1 / Phase 2 | 2025-03-03 |
| Recruiting | Reproductive and Mental Health of Patients With Aplastic Anemia Aplastic Anemia, Reproductive Health | — | 2025-03-03 |
| Recruiting | Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model Acute Graft-versus-Host Disease | Phase 2 | 2025-03-03 |
| Recruiting | An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia Immune Thrombocytopenia (ITP), Treatment | Phase 2 | 2025-03-03 |
| Recruiting | A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP Herombopag | Phase 2 | 2025-03-03 |
| Recruiting | Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 / Phase 3 | 2025-03-03 |
| Recruiting | Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia CAR T-cell Therapy, Autoimmune Hemolytic Anemia, Brain Function | — | 2025-02-25 |
| Recruiting | The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Functi Poor Graft Function | Phase 1 | 2025-02-14 |
| Recruiting | CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathy | Phase 1 | 2025-02-11 |
| Completed | Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single Mucormycosis, Hematologic Malignancies, COVID-19 | — | 2025-02-08 |
| Recruiting | BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma Multiple Myeloma | Phase 2 | 2025-02-05 |
| Recruiting | Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia Sever Aplastic Anaemia, Elderly (People Aged 65 or More), Immunosuppressive Treatment | Phase 2 | 2025-02-01 |
| Not Yet Recruiting | A Study of the Effect of Laughter Therapy on the Mental Health and Quality of Survival of Hematopoietic Stem C Hematologic Malignancy, Hematopoietic Stem Cell Transplant | N/A | 2025-01-31 |
| Not Yet Recruiting | Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic Anemia Aplastic Anaemia, HSCT, TBI | Phase 2 | 2025-01-31 |
| Recruiting | Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML CML,Blast Phase | Phase 1 / Phase 2 | 2025-01-26 |
| Recruiting | HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML AML | Phase 2 | 2025-01-21 |
| Recruiting | Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT AML (Acute Myelogenous Leukemia) | Phase 2 | 2025-01-20 |
| Not Yet Recruiting | A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy, Failure ≥3 Lines of Therapies | Phase 1 | 2025-01-16 |
| Recruiting | A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia Immune Thrombocytopenia, Treatment | Phase 1 / Phase 2 | 2025-01-15 |
| Recruiting | Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1- AML, RUNX1-RUNX1T1 Fusion Protein Expression | Phase 3 | 2025-01-10 |
| Recruiting | Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 / Phase 3 | 2025-01-03 |
| Not Yet Recruiting | BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction The AL Amyloidosis | N/A | 2025-01-01 |
| Not Yet Recruiting | Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk A AML | N/A | 2025-01-01 |
| Not Yet Recruiting | Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With AML | N/A | 2024-12-31 |
| Not Yet Recruiting | BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma High Risk Smoldering Multiple Myeloma | N/A | 2024-12-30 |
| Recruiting | JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia | Phase 2 | 2024-12-25 |
| Recruiting | CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy. Autoimmune Hemolytic Anemia, CD19/BCMA CAR T-cells, Universal Allogeneic CAR T-cells | Phase 1 | 2024-12-05 |
| Recruiting | Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia Thalassemia Intermedia, Thalassemia Major, Growth Delay | N/A | 2024-12-01 |
| Not Yet Recruiting | Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Peripheral T Cell Lymphoma | Phase 1 | 2024-12-01 |
| Recruiting | CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases Autoimmune Diseases | EARLY_Phase 1 | 2024-11-15 |
| Active Not Recruiting | EPOCH-Economics and Patient Outcomes in China in Haemophilia Hemophilia | — | 2024-11-14 |
| Not Yet Recruiting | Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), HSCT, Tyrosine Kinase Inhibitor | Phase 2 | 2024-11-01 |
| Recruiting | Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Ane Severe Aplastic Anemia, Cyclophosphamide Reduced-dose, Immunosuppressive Therapy | Phase 2 | 2024-11-01 |
| Not Yet Recruiting | Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post All B-ALL | N/A | 2024-11-01 |
| Recruiting | Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic A Aplastic Anemia, TPO Receptor Agonists | Phase 2 | 2024-10-24 |
| Recruiting | The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation FLT3 Gene Mutation, AML | Phase 1 / Phase 2 | 2024-10-08 |
| Withdrawn | Tislelizumab with Azacitidine in the Treatment of R/R AML Refractory AML, Relapsed Adult AML | Phase 1 / Phase 2 | 2024-10-05 |
| Not Yet Recruiting | Twice-per-weekSelinexor, 2 Days Melphalan Acute Myeloid Leukemia | Phase 3 | 2024-09-30 |
| Recruiting | Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML AML (Acute Myelogenous Leukemia) | Phase 2 | 2024-09-29 |
| Recruiting | Intermediate-dose HAD Regimen for CEBPA Double-mutated AML AML | N/A | 2024-08-13 |
| Recruiting | PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia | Phase 2 | 2024-08-10 |
| Recruiting | Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia T-LGL Leukemia, NK-LGL Leukemia | Phase 2 | 2024-08-10 |
| Recruiting | Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia AML, Acute Myeloid Leukemia | N/A | 2024-08-05 |
| Recruiting | Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP) Immune Thrombocytopenia, Treatment | Phase 2 | 2024-08-01 |
| Recruiting | Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescen B-cell Acute Lymphoblastic Leukemia | Phase 2 | 2024-08-01 |
| Not Yet Recruiting | Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis Hematopoietic Stem Cell Transplantation | Phase 3 | 2024-07-31 |
| Not Yet Recruiting | Prospective Observational Clinical Study on Changes in Cognitive Levels in Elderly Patients Before and After H Hematopoietic Stem Cell Transplantation | — | 2024-07-30 |
| Recruiting | Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diag Mantle Cell Lymphoma | Phase 2 | 2024-07-18 |
| Recruiting | Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas Marginal Zone Lymphoma | Phase 2 | 2024-07-11 |
| Recruiting | Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leu Acute Lymphoid Leukemia | Phase 2 | 2024-07-02 |
| Not Yet Recruiting | The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation B-ALL | N/A | 2024-07-01 |
| Not Yet Recruiting | the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic Leuke Acute Lymphoblastic Leukemia | — | 2024-07-01 |
| Not Yet Recruiting | Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD Acute Graft Versus Host Disease | Phase 2 | 2024-07-01 |
| Not Yet Recruiting | Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI Acute Graft-versus-host Disease | N/A | 2024-07-01 |
| Recruiting | Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Acute Lymphoblastic Leukemia ALL | Phase 2 | 2024-06-25 |
| Recruiting | Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult | N/A | 2024-06-10 |
| Recruiting | Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult | N/A | 2024-06-04 |
| Recruiting | A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP Primary Immune Thrombocytopenia | Phase 2 | 2024-06-01 |
| Not Yet Recruiting | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | 2024-05-30 |
| Recruiting | R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | 2024-05-30 |
| Recruiting | Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL Relapsed/Refractory Large B-Cell Lymphoma | Phase 2 | 2024-05-28 |
| Recruiting | MRD-positive AML Clinical Study AML, Adult | N/A | 2024-05-11 |
| Active Not Recruiting | A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in B-cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | 2024-04-30 |
| Completed | Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia | Phase 2 | 2024-04-17 |
| Recruiting | VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT Relapse Acute Myeloid Leukemia | Phase 2 | 2024-04-12 |
| Recruiting | Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | 2024-04-02 |
| Recruiting | Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia Immune Thrombocytopenia, Treatment | Phase 2 | 2024-03-01 |
| Recruiting | Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstituti Transplant-Related Disorder | N/A | 2024-02-29 |
| Recruiting | Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia AML, Refractory, Relapsed | N/A | 2024-02-22 |
| Active Not Recruiting | CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. Autoimmune Hemolytic Anemia, Autologous CD19 CAR-T, Failure of Three or More Lines of Therapy | Phase 1 | 2024-02-04 |
| Unknown | Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA Anemia, Aplastic | Phase 2 | 2024-02-01 |
| Unknown | CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy Autoimmune Hemolytic Anemia, CD19 CAR-T Cell Infusion | Phase 1 | 2024-01-20 |
| Recruiting | GVM±R in Patients With Relapsed or Refractory Aggressive NHL. Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 2 | 2024-01-17 |
| Recruiting | Safety and Efficacy Study of NGGT003 in Hemophilia A Patients Hemophilia A | EARLY_Phase 1 | 2024-01-17 |
| Active Not Recruiting | A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of I Immune Thrombocytopenia, Treatment | Phase 2 | 2024-01-16 |
| Recruiting | Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients Transfusion-dependent Beta-Thalassemia | N/A | 2024-01-04 |
| Active Not Recruiting | Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed | Phase 1 | 2024-01-01 |
| Recruiting | Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP) Immune Thrombocytopenia, Treatment | Phase 2 | 2023-12-28 |
| Recruiting | Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia Relapsed/Refractory Large Granular T Lymphocytic Leukemia | Phase 2 | 2023-12-03 |
| Recruiting | A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Th Immune Thrombocytopenia, Treatment | Phase 2 | 2023-12-01 |
| Recruiting | DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma Multiple Myeloma | Phase 2 | 2023-12-01 |
| Recruiting | Anti-CD38 Antibody Treating Evans Syndrome Evan Syndrome, Treatment | Phase 2 | 2023-12-01 |
| Recruiting | Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma B Cell Lymphoma | Phase 2 | 2023-11-30 |
| Recruiting | Cohort of Nursing Homes Health Status | — | 2023-11-30 |
| Unknown | An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Trans RSV Infection | — | 2023-11-30 |
| Not Yet Recruiting | Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML Acute Myeloid Leukemia | Phase 2 | 2023-11-24 |
| Recruiting | ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibit Hemophilia A With Inhibitor | Phase 4 | 2023-11-22 |
| Recruiting | Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation | — | 2023-11-16 |
| Recruiting | Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP) Primary Immune Thrombocytopenia | — | 2023-11-01 |
| Recruiting | A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia C-KIT Mutation | — | 2023-11-01 |
| Unknown | A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidam Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | 2023-10-30 |
| Recruiting | Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemothera Acute Myeloid Leukemia | N/A | 2023-10-01 |
| Unknown | The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia Refractory/Relapsed Autoimmune Hemolytic Anemia | Phase 2 | 2023-09-01 |
| Recruiting | Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells Thalassemia, Beta, Thalassemia Major | N/A | 2023-08-31 |
| Recruiting | A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia Immune Thrombocytopenia, Treatment | Phase 2 | 2023-08-28 |
| Recruiting | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Tr Plasma Cell Leukemia | Phase 2 | 2023-08-14 |
| Completed | Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia Acute Myeloid Leukemia | N/A | 2023-08-08 |
| Enrolling By Invitation | Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD Invasive Fungal Disease, Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation | — | 2023-08-01 |
| Recruiting | Anti-CD38 Antibody Treating APS With Thrombocytopenia Antiphospholipid Syndrome, Thrombocytopenia | Phase 2 | 2023-08-01 |
| Completed | Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia AML, Adult, Minimal Residual Disease | Phase 1 | 2023-07-31 |
| Active Not Recruiting | Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients Severe Aplastic Anemia | Phase 2 | 2023-07-10 |
| Unknown | Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT | Phase 2 | 2023-07-07 |
| Recruiting | The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes Lower Risk MDS Per IPSS-R | Phase 2 | 2023-07-01 |
| Unknown | Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation | Phase 4 | 2023-07-01 |
| Unknown | Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation | Phase 4 | 2023-07-01 |
| Unknown | Ruxolitinib as GVHD Prophylaxis in AA Patients The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA | Phase 2 | 2023-07-01 |
| Recruiting | Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV Polycythemia Vera | Phase 2 | 2023-06-30 |
| Recruiting | YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma Relapsed or Refractory Multiple Myeloma | Phase 1 | 2023-06-28 |
| Unknown | A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID COVID-19, Hematopoietic Stem Cell Transplantation | N/A | 2023-06-10 |
| Recruiting | Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene The Transfusion-dependent Beta-Thalassemia, Gene Therapy | — | 2023-06-05 |
| Recruiting | BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT Multiple Myeloma | Phase 2 | 2023-05-29 |
| Active Not Recruiting | Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalass Transfusion-dependent Beta-Thalassemia | N/A | 2023-05-23 |
| Recruiting | An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Ac Acquired Hemophilia | Phase 4 | 2023-05-22 |
| Terminated | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemo Acute Myeloid Leukemia, Adult | Phase 1 / Phase 2 | 2023-05-05 |
| Unknown | Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Abe Multiple Myeloma | — | 2023-05-01 |
| Recruiting | A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leuk Plasma Cell Leukemia | Phase 2 | 2023-04-25 |
| Recruiting | A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities Multiple Myeloma | Phase 2 | 2023-04-21 |
| Recruiting | The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients. Hemophilia B | N/A | 2023-04-19 |
| Completed | Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia Aplastic Anemia, Platelet Transfusion Refractoriness | Phase 1 | 2023-04-17 |
| Active Not Recruiting | A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnos Multiple Myeloma | Phase 2 | 2023-04-04 |
| Recruiting | Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old Hemophilia B | Phase 1 | 2023-03-23 |
| Recruiting | Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treat Peripheral T Cell Lymphoma, Epigenetic Repression | Phase 2 | 2023-03-02 |
| Recruiting | Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness Severe Aplastic Anemia, Platelet Transfusion Refractoriness | Phase 2 | 2023-02-23 |
| Unknown | TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Primary Immune Thrombocytopenia (ITP) | Phase 4 | 2023-02-23 |
| Completed | LILRB4 STAR-T Cell Therapy for Monocytic Leukemia Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia | N/A | 2023-02-16 |
| Recruiting | Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM Waldenstrom Macroglobulinemia | Phase 2 | 2023-02-15 |
| Completed | Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia Relapsed/Refractory Large Granular T Lymphocytic Leukemia | Phase 1 | 2023-02-10 |
| Completed | Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia Transfusion Dependent Beta-Thalassaemia | N/A | 2023-02-10 |
| Unknown | Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model Transplant-Related Disorder | Phase 2 | 2023-02-09 |
| Completed | A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia Immune Thrombocytopenia, Treatment | Phase 2 | 2023-01-22 |
| Completed | Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model Transplant-Related Disorder | Phase 2 | 2023-01-15 |
| Terminated | PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment | Phase 1 | 2023-01-13 |
| Unknown | Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantati Hematological Disease, Allogeneic Hematopoietic Stem Cell Transplantation | N/A | 2023-01-01 |
| Completed | The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19) COVID-19 | Phase 1 / Phase 2 | 2022-12-16 |
| Terminated | CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 | 2022-12-12 |
| Active Not Recruiting | A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytope Immune Thrombocytopenia | Phase 2 | 2022-12-10 |
| Completed | Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia Non Severe Aplastic Anemia, Untreated | Phase 2 | 2022-12-01 |
| Completed | A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts Previously Treated Primary Immune Thrombocytopenia | Phase 4 | 2022-11-22 |
| Unknown | Avatrombopag Combined With IST as First-line Treatment for SAA Severe Aplastic Anemia | Phase 2 | 2022-11-10 |
| Recruiting | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Stud Follicular Lymphoma | — | 2022-11-01 |
| Recruiting | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma Marginal Zone Lymphoma | Phase 2 | 2022-11-01 |
| Unknown | A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Pos Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease | N/A | 2022-10-30 |
| Active Not Recruiting | Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Resi Acute Lymphocytic Leukemia | Phase 2 | 2022-10-18 |
| Terminated | Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease Minimal Residual Disease | Phase 1 | 2022-10-09 |
| Completed | Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Phase 2 | 2022-10-08 |
| Recruiting | The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients. Hemophilia A | N/A | 2022-09-29 |
| Unknown | Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemi Acute Myeloid Leukemia, Childhood, Relapsed Leukemia, Refractory Leukemia | EARLY_Phase 1 | 2022-09-14 |
| Completed | CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies Hematological Malignancies | Phase 2 | 2022-09-07 |
| Unknown | Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Diseas aGVHD | N/A | 2022-09-01 |
| Unknown | Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma Multiple Myeloma | Phase 1 | 2022-09-01 |
| Unknown | Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia | Phase 1 | 2022-09-01 |
| Unknown | ctDNA Methylation Sequencing for Myeloma Multiple Myeloma | — | 2022-08-31 |
| Recruiting | Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphi Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | 2022-08-01 |
| Recruiting | A Study of FVIII Gene Therapy for Hemophilia A Hemophilia A | EARLY_Phase 1 | 2022-07-19 |
| Recruiting | ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM) Multiple Myeloma | Phase 1 / Phase 2 | 2022-07-14 |
| Terminated | Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients Acute Myeloid Leukemia, Measurable Disease | Phase 2 | 2022-06-29 |
| Unknown | Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Fu Aplastic Anemia | N/A | 2022-06-28 |
| Unknown | Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute L Acute Leukemia | N/A | 2022-06-06 |
| Unknown | A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency Severe Aplastic Anemia | N/A | 2022-06-05 |
| Unknown | Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly Severe Aplastic Anemia | N/A | 2022-06-01 |
| Unknown | The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA Refractory Aplastic Anemia | N/A | 2022-06-01 |
| Unknown | Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia Essential Thrombocytopenia | Phase 2 | 2022-06-01 |
| Active Not Recruiting | Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 2 / Phase 3 | 2022-05-19 |
| Active Not Recruiting | GVM±R in Patients With Relapsed or Refractory Aggressive NHL Non Hodgkin Lymphoma | Phase 1 | 2022-05-15 |
| Recruiting | Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma Multiple Myeloma, Lymphoma | Phase 2 | 2022-04-26 |
| Terminated | Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia AML, Adult | Phase 1 | 2022-03-26 |
| Unknown | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed | Phase 2 | 2022-03-22 |
| Recruiting | Herombopag for Chemotherapy-induced Thrombocytopenia Chemotherapy-induced Thrombocytopenia, Herombopag | Phase 2 | 2022-03-14 |
| Terminated | A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Acute Lymphocytic Leukemia | Phase 1 | 2022-03-14 |
| Terminated | Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | Phase 1 | 2022-03-14 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients Hemophilia B | Phase 1 / Phase 2 | 2022-02-16 |
| Recruiting | A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia Immune Thrombocytopenia, Treatment | Phase 2 | 2022-02-15 |
| Recruiting | Avatrombopag for Chemotherapy-induced Thrombocytopenia Chemotherapy-induced Thrombocytopenia, Avatrombopag | Phase 2 | 2022-02-10 |
| Recruiting | Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytope Antiphospholipid Syndrome, Thrombocytopenia, Treatment | Phase 2 | 2022-01-25 |
| Unknown | PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Cla Hodgkin Lymphoma, Adult, Relapse, Refractory Hodgkin Lymphoma | Phase 2 | 2022-01-01 |
| Unknown | Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma Multiple Myeloma | — | 2021-12-31 |
| Recruiting | Safety and Tolerability of VGB-R04 in Patients With Haemophilia B Hemophilia B | EARLY_Phase 1 | 2021-12-28 |
| Terminated | Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL Acute Leukemia | Phase 4 | 2021-09-16 |
| Recruiting | Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Immune Thrombocytopenia, Autoantibodies, Evan Syndrome | Phase 2 | 2021-09-01 |
| Unknown | R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL Richter Transformation | Phase 2 | 2021-08-30 |
| Unknown | TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Immune Thrombocytopenia (ITP), Autoantibodies, Evan Syndrome | Phase 2 / Phase 3 | 2021-06-06 |
| Recruiting | National Longitudinal Cohort of Hematological Diseases (NICHE) - CART Hematological Malignancies | — | 2021-06-01 |
| Recruiting | TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years Primary Immune Thrombocytopenic Purpura | N/A | 2021-05-30 |
| Terminated | Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia Refractory Aplastic Anemia | Phase 2 | 2021-04-22 |
| Recruiting | Gene Therapy for Chinese Hemophilia A Hemophilia A, Gene Therapy | N/A | 2021-03-04 |
| Completed | Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation Patients Pulmonary Fungal Infection | — | 2021-02-08 |
| Completed | CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma Large B-cell Lymphoma | Phase 1 / Phase 2 | 2021-01-01 |
| Recruiting | Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions. Allergic Transfusion Reaction | Phase 2 | 2021-01-01 |
| Recruiting | Eltrombopag for Chemotherapy-induced Thrombocytopenia Chemotherapy-induced Thrombocytopenia, Eltrombopag | Phase 2 | 2020-12-31 |
| Unknown | Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Non-Hodgkin's Lymphoma (NHL), Peripheral T Cell Lymphoma (PTCL) | EARLY_Phase 1 | 2020-12-31 |
| Recruiting | National Longitudinal Cohort of Hematological Diseases Multiple Myeloma, Acute Myeloid Leukemia, Hemophilia | — | 2020-12-01 |
| Completed | Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment Acquired Pure Red Cell Aplasia | Phase 2 | 2020-09-13 |
| Unknown | Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) Primary Immune Thrombocytopenia (ITP) | Phase 4 | 2020-08-10 |
| Recruiting | Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous L Acute Leukemia of Ambiguous Lineage | Phase 2 | 2020-07-08 |
| Active Not Recruiting | Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Le CEBPA Double Mutation, Acute Myeloid Leukemia | Phase 2 | 2020-06-01 |
| Completed | Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia Waldenström Macroglobulinemia | Phase 2 | 2020-06-01 |
| Active Not Recruiting | The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia Refractory/Relapsed Autoimmune Hemolytic Anemia | Phase 2 | 2020-05-01 |
| Recruiting | Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythe Essential Thrombocytopenia | Phase 2 | 2020-01-10 |
| Completed | Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopen Thrombocytopenia, Mesenchymal Stem Cells | N/A | 2019-11-21 |
| Completed | Gene Therapy for Chinese Hemophilia B Hemophilia B | N/A | 2019-10-16 |
| Unknown | γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Non-Hodgkin's Lymphoma, Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma, Chronic Lymphoblastic Leukemia | EARLY_Phase 1 | 2019-10-01 |
| Terminated | CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | EARLY_Phase 1 | 2019-09-30 |
| Completed | A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy Diffuse Large B Cell Lymphoma | Phase 1 | 2019-09-29 |
| Completed | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma Multiple Myeloma | Phase 1 | 2019-09-12 |
| Recruiting | A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With Chronic Lymphocytic Leukemia | Phase 2 | 2019-05-15 |
| Recruiting | Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients Thrombocytopenia, Splenectomy | — | 2019-01-23 |
| Unknown | DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma | Phase 2 | 2019-01-21 |
| Completed | to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection Thrombocytopenia Purpura, Chronic HBV Infection | Phase 2 | 2018-12-04 |
| Withdrawn | Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation Relapsed AML, T(8;21), C-KIT Mutation | Phase 1 | 2018-07-01 |
| Completed | Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma | Phase 1 | 2018-06-08 |
| Unknown | a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Plasmacytoma | N/A | 2018-01-05 |
| Completed | Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituxim Acquired Hemophilia A | Phase 4 | 2017-12-29 |
| Terminated | The Mutation Profile and Prognosis in AML With IDH1/2 Mutation AML | — | 2017-12-21 |
| Completed | CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma Lymphomas Non-Hodgkin's B-Cell, Relapse | Phase 1 | 2017-06-08 |
| Completed | Data Registry in Chinese Hemophilia A and B Patients Hemophilia A, Hemophilia B | — | 2017-05-07 |
| Active Not Recruiting | Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML AML | Phase 3 | 2017-02-08 |
| Enrolling By Invitation | Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia AML | Phase 1 / Phase 2 | 2017-02-08 |
| Active Not Recruiting | Efficacy and Safety of Chidamide in CBF Leukemia AML | Phase 1 / Phase 2 | 2017-02-08 |
| Withdrawn | Efficacy of Decitabine in Clearance of MRD AML | Phase 1 / Phase 2 | 2017-02-08 |
| Completed | CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukaemia Recurrent | Phase 1 | 2016-11-01 |
| Completed | Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML Acute Myeloid Leukemia | Phase 2 | 2016-10-01 |
| Unknown | The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia Acute Myeloid Leukemia | N/A | 2016-08-01 |
| Completed | The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Waldenström Macroglobulinemia | Phase 4 | 2016-05-01 |
| Completed | The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Waldenström Macroglobulinemia | Phase 4 | 2016-05-01 |
| Completed | Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Waldenström Macroglobulinemia | Phase 4 | 2016-05-01 |
| Completed | EDOCH Alternating With DHAP for New Diagnosed Younger MCL Mantle Cell Lymphoma | Phase 4 | 2016-01-01 |
| Completed | Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Acute,Leukemia, Lymphoid | Phase 2 | 2015-08-01 |
| Completed | Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Thrombocytopenia | Phase 4 | 2014-10-01 |
| Completed | A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia Aplastic Anemia | Phase 2 | 2014-08-01 |
| Completed | Umbilical Cord Mesenchymal Stem Cells Injection for Peripheral Arterial Disease Peripheral Arterial Disease | Phase 1 / Phase 2 | 2014-02-01 |
| Unknown | TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL T-LGL Leukemia, Clpd-Nk | Phase 2 / Phase 3 | 2013-05-20 |
| Unknown | Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturn Paroxysmal Nocturnal Hemoglobinuria, Hemoglobinuria, Hemoglobinuria, Paroxysmal | Phase 2 | 2013-01-01 |
| Completed | Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia Immune Thrombocytopenic Purpura | N/A | 2012-10-01 |
| Unknown | Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal H Paroxysmal Nocturnal Hemoglobinuria, Hemoglobinuria, Hemoglobinuria, Paroxysmal | Phase 2 | 2012-07-01 |
| Unknown | Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic An Anemia, Anemia, Hemolytic, Anemia, Hemolytic, Autoimmune | Phase 2 | 2012-04-01 |
| Completed | Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial fo Acute Myeloid Leukemia, Pediatric | — | 2005-04-10 |
| Recruiting | National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia Mixed Type | — | 2001-01-01 |
| Recruiting | National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia T-LGL Leukemia, NK-LGL Leukemia | — | 2000-01-01 |
| Available | A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies Relapsed and Refractory Hematological Malignancies | — | — |